Dr. Karen Harris -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Karen Harris, a Neurology physician based in City, SC. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Karen Harris has received $4,478.14 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Karen Harris has received a total of $4,478.14 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $4,478.14 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Karen Harris's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Travel & Lodging$4,478.14Transportation and hotel expenses for conferences and meetings

The largest payment category for Dr. Karen Harris is Travel & Lodging, accounting for 100% ($4,478.14) of total pharmaceutical payments received. This represents the primary type of financial relationship between Dr. Karen Harris and pharmaceutical companies.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Karen Harris. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
AbbVie Inc$4,478.141

Dr. Karen Harris has a financial relationship with AbbVie Inc, receiving $4,478.14 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

Drugs and Medical Devices Referenced in Payments

The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Karen Harris. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.

The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Karen Harris's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Karen Harris has received $4.5K across 1 pharmaceutical payments as a Neurology physician in City, SC. Top paying companies include AbbVie Inc ($4.5K). Dr. Harris received a single payment of $4,478 in 2024, which is her only recorded payment. This payment was entirely for travel expenses, indicating a potential focus on educational or conference-related activities. The payment originated from AbbVie Inc., a major pharmaceutical company, and was associated with the drug Humira.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Karen Harris is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may want to inquire about how pharmaceutical company sponsored travel or education might influence their doctor's treatment recommendations, though it's important to remember these payments often support valuable medical learning. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Karen Harris Compares to Other Neurology Physicians

For neurologists, receiving a single, substantial payment for travel from a pharmaceutical company is not uncommon, especially if it's related to attending major medical conferences or specialized training.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Karen Harris in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
AbbVie Inc$4,478.14travelHumira2024-06-14Not Assessed

Frequently Asked Questions About Dr. Karen Harris's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Karen Harris received?

Karen Harris has received a total of $4.5K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Karen Harris taking too much pharma money?

Karen Harris has received $4.5K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Neurology), the types of payments, and how they compare to peers. The largest payment category is travel ($4.5K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Karen Harris?

The top pharmaceutical companies paying Karen Harris are: AbbVie Inc ($4.5K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Karen Harris receive?

Karen Harris's payments by type: travel: $4.5K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Karen Harris's payments compare to other Neurology doctors?

To compare, look at the total amount ($4.5K), number of payments (1), and the types of payments received. Neurology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Karen Harris's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1067199539). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Karen Harris's pharma payment profile?

The doctor's payment profile is highly concentrated, with 100% of her total payments coming from a single company. Karen Harris has received $4.5K in total pharma payments.

How does Karen Harris compare to peers in Neurology?

For neurologists, receiving a single, substantial payment for travel from a pharmaceutical company is not uncommon, especially if it's related to attending major medical conferences or specialized training.

Are Karen Harris's pharma relationships typical for Neurology?

The sole payment received is significantly higher than the average payment for many physicians, suggesting a substantial expense covered.

What should patients of Karen Harris know about these payments?

Patients may want to inquire about how pharmaceutical company sponsored travel or education might influence their doctor's treatment recommendations, though it's important to remember these payments often support valuable medical learning.

What patterns are visible in Karen Harris's payment history?

The data suggests a strong relationship with AbbVie Inc., potentially due to the drug Humira, which is a common treatment for various inflammatory conditions.

Understanding This Doctor Payment Report

This transparency report for Dr. Karen Harris is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Karen Harris's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Karen Harris and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.